Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism

Shinichiro Tada, Hidetsugu Saito, Hirotoshi Ebinuma, Keisuke Ojiro, Yoshiyuki Yamagishi, Naoki Kumagai, Yasutaka Inagaki, Tetsuya Masuda, Jiro Nishida, Masahiko Takahashi, Hiroshi Nagata, Toshifumi Hibi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aim: We investigated lipid metabolism in patients with chronic hepatitis C virus (HCV), serotype 1, undergoing combination therapy with PEG-IFN α-2b (PEG-IFN) and ribavirin (RBV). Methods: A total of 185 patients with chronic HCV (HCV serotype 1; HCV RNA levels ≥ 100KIU/mL) who received a combination of PEG-IFN and RBV were enrolled. Results: Sustained virological response (SVR) was obtained in 82 cases (44.3%). The median age, red blood cell and platelet counts differed significantly between the SVR and non-SVR groups before treatment. However there was no significant difference between total cholesterol (TC), LDL-cholesterol (LDL-C) and triglyceride (TG) levels before treatment. TC and LDL-C levels decreased during the treatment in both groups. In the SVR group, TC and LDL-C levels increased quickly after the end of the treatment and were higher than those before treatment. On the other hand, TC and LDL-C levels returned to pretreatment levels in the non-SVR group and were significantly lower than in the SVR group. TG levels were elevated in both groups after the beginning of treatment. After the end of treatment, this elevation persisted in the SVR group, while TG levels returned to pre-treatment levels in the non-SVR group. There was a significant difference in TG levels at 24weeks after the end of the treatment between the 2 groups. In the non-SVR group some patients achieved normalization of ALT (alanine aminotransferase) but persistence of normal ALT levels did not contribute to the increase of TC and TG. Conclusion: TC, LDL-C and TG levels increase only in patients with HCV, serotype 1, undergoing combination therapy when a SVR is achieved.

Original languageEnglish
Pages (from-to)195-199
Number of pages5
JournalHepatology Research
Volume39
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Ribavirin
Lipid Metabolism
Hepacivirus
Interferons
LDL Cholesterol
Cholesterol
Triglycerides
Therapeutics
Chronic Hepatitis C
Alanine Transaminase
Erythrocyte Count
Platelet Count
RNA

Keywords

  • Chronic hepatitis C virus
  • PEG-IFN
  • Ribavirin
  • Total cholesterol
  • Triglyceride

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. / Tada, Shinichiro; Saito, Hidetsugu; Ebinuma, Hirotoshi; Ojiro, Keisuke; Yamagishi, Yoshiyuki; Kumagai, Naoki; Inagaki, Yasutaka; Masuda, Tetsuya; Nishida, Jiro; Takahashi, Masahiko; Nagata, Hiroshi; Hibi, Toshifumi.

In: Hepatology Research, Vol. 39, No. 2, 2009, p. 195-199.

Research output: Contribution to journalArticle

Tada, S, Saito, H, Ebinuma, H, Ojiro, K, Yamagishi, Y, Kumagai, N, Inagaki, Y, Masuda, T, Nishida, J, Takahashi, M, Nagata, H & Hibi, T 2009, 'Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism', Hepatology Research, vol. 39, no. 2, pp. 195-199. https://doi.org/10.1111/j.1872-034X.2008.00439.x
Tada, Shinichiro ; Saito, Hidetsugu ; Ebinuma, Hirotoshi ; Ojiro, Keisuke ; Yamagishi, Yoshiyuki ; Kumagai, Naoki ; Inagaki, Yasutaka ; Masuda, Tetsuya ; Nishida, Jiro ; Takahashi, Masahiko ; Nagata, Hiroshi ; Hibi, Toshifumi. / Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. In: Hepatology Research. 2009 ; Vol. 39, No. 2. pp. 195-199.
@article{faa24e345fe14e71b29d36076d860b11,
title = "Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism",
abstract = "Aim: We investigated lipid metabolism in patients with chronic hepatitis C virus (HCV), serotype 1, undergoing combination therapy with PEG-IFN α-2b (PEG-IFN) and ribavirin (RBV). Methods: A total of 185 patients with chronic HCV (HCV serotype 1; HCV RNA levels ≥ 100KIU/mL) who received a combination of PEG-IFN and RBV were enrolled. Results: Sustained virological response (SVR) was obtained in 82 cases (44.3{\%}). The median age, red blood cell and platelet counts differed significantly between the SVR and non-SVR groups before treatment. However there was no significant difference between total cholesterol (TC), LDL-cholesterol (LDL-C) and triglyceride (TG) levels before treatment. TC and LDL-C levels decreased during the treatment in both groups. In the SVR group, TC and LDL-C levels increased quickly after the end of the treatment and were higher than those before treatment. On the other hand, TC and LDL-C levels returned to pretreatment levels in the non-SVR group and were significantly lower than in the SVR group. TG levels were elevated in both groups after the beginning of treatment. After the end of treatment, this elevation persisted in the SVR group, while TG levels returned to pre-treatment levels in the non-SVR group. There was a significant difference in TG levels at 24weeks after the end of the treatment between the 2 groups. In the non-SVR group some patients achieved normalization of ALT (alanine aminotransferase) but persistence of normal ALT levels did not contribute to the increase of TC and TG. Conclusion: TC, LDL-C and TG levels increase only in patients with HCV, serotype 1, undergoing combination therapy when a SVR is achieved.",
keywords = "Chronic hepatitis C virus, PEG-IFN, Ribavirin, Total cholesterol, Triglyceride",
author = "Shinichiro Tada and Hidetsugu Saito and Hirotoshi Ebinuma and Keisuke Ojiro and Yoshiyuki Yamagishi and Naoki Kumagai and Yasutaka Inagaki and Tetsuya Masuda and Jiro Nishida and Masahiko Takahashi and Hiroshi Nagata and Toshifumi Hibi",
year = "2009",
doi = "10.1111/j.1872-034X.2008.00439.x",
language = "English",
volume = "39",
pages = "195--199",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism

AU - Tada, Shinichiro

AU - Saito, Hidetsugu

AU - Ebinuma, Hirotoshi

AU - Ojiro, Keisuke

AU - Yamagishi, Yoshiyuki

AU - Kumagai, Naoki

AU - Inagaki, Yasutaka

AU - Masuda, Tetsuya

AU - Nishida, Jiro

AU - Takahashi, Masahiko

AU - Nagata, Hiroshi

AU - Hibi, Toshifumi

PY - 2009

Y1 - 2009

N2 - Aim: We investigated lipid metabolism in patients with chronic hepatitis C virus (HCV), serotype 1, undergoing combination therapy with PEG-IFN α-2b (PEG-IFN) and ribavirin (RBV). Methods: A total of 185 patients with chronic HCV (HCV serotype 1; HCV RNA levels ≥ 100KIU/mL) who received a combination of PEG-IFN and RBV were enrolled. Results: Sustained virological response (SVR) was obtained in 82 cases (44.3%). The median age, red blood cell and platelet counts differed significantly between the SVR and non-SVR groups before treatment. However there was no significant difference between total cholesterol (TC), LDL-cholesterol (LDL-C) and triglyceride (TG) levels before treatment. TC and LDL-C levels decreased during the treatment in both groups. In the SVR group, TC and LDL-C levels increased quickly after the end of the treatment and were higher than those before treatment. On the other hand, TC and LDL-C levels returned to pretreatment levels in the non-SVR group and were significantly lower than in the SVR group. TG levels were elevated in both groups after the beginning of treatment. After the end of treatment, this elevation persisted in the SVR group, while TG levels returned to pre-treatment levels in the non-SVR group. There was a significant difference in TG levels at 24weeks after the end of the treatment between the 2 groups. In the non-SVR group some patients achieved normalization of ALT (alanine aminotransferase) but persistence of normal ALT levels did not contribute to the increase of TC and TG. Conclusion: TC, LDL-C and TG levels increase only in patients with HCV, serotype 1, undergoing combination therapy when a SVR is achieved.

AB - Aim: We investigated lipid metabolism in patients with chronic hepatitis C virus (HCV), serotype 1, undergoing combination therapy with PEG-IFN α-2b (PEG-IFN) and ribavirin (RBV). Methods: A total of 185 patients with chronic HCV (HCV serotype 1; HCV RNA levels ≥ 100KIU/mL) who received a combination of PEG-IFN and RBV were enrolled. Results: Sustained virological response (SVR) was obtained in 82 cases (44.3%). The median age, red blood cell and platelet counts differed significantly between the SVR and non-SVR groups before treatment. However there was no significant difference between total cholesterol (TC), LDL-cholesterol (LDL-C) and triglyceride (TG) levels before treatment. TC and LDL-C levels decreased during the treatment in both groups. In the SVR group, TC and LDL-C levels increased quickly after the end of the treatment and were higher than those before treatment. On the other hand, TC and LDL-C levels returned to pretreatment levels in the non-SVR group and were significantly lower than in the SVR group. TG levels were elevated in both groups after the beginning of treatment. After the end of treatment, this elevation persisted in the SVR group, while TG levels returned to pre-treatment levels in the non-SVR group. There was a significant difference in TG levels at 24weeks after the end of the treatment between the 2 groups. In the non-SVR group some patients achieved normalization of ALT (alanine aminotransferase) but persistence of normal ALT levels did not contribute to the increase of TC and TG. Conclusion: TC, LDL-C and TG levels increase only in patients with HCV, serotype 1, undergoing combination therapy when a SVR is achieved.

KW - Chronic hepatitis C virus

KW - PEG-IFN

KW - Ribavirin

KW - Total cholesterol

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=59149088608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149088608&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2008.00439.x

DO - 10.1111/j.1872-034X.2008.00439.x

M3 - Article

C2 - 19054155

AN - SCOPUS:59149088608

VL - 39

SP - 195

EP - 199

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 2

ER -